Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status (Q57217085)
Jump to navigation
Jump to search
article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status |
article |
Statements
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status (English)
Lynda Roman
Carol Aghajanian
Ursula A Matulonis
Michael S Gordon
Molly Brewer
Gini F Fleming
Agustin A Garcia
Mark D Pegram
Russell J Schilder
Mika K Derynck
Kimmie Ng
Benjamin Lyons
David E Allison
David A Eberhard
Thinh Q Pham
Randall C Dere
Beth Y Karlan
John D Hainsworth